Biogen ALS Drug Showed No Benefit, O'Neill Says

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)
Is Tesla’s Downgrade an Opportunity for Investors
22:07 - IDDS Group co-founder and CEO Max Zanan and Jefferies Analyst Dan Dolev discuss the Tesla being downgraded with Emily Chang on “Bloomberg West.” (Source: Bloomberg)
  • Ukraine’s Jaresko: I'm Optimistic About Russia Bond Talks
  • Dell to Offer Data Storage Giant EMC $33 Per Share
  • Uber Closing In On 2014 Hack Suspect